Company Insights

TOMZ customer relationships

Explore interactive graphBrowse insights index
TOMZ customer relationship map

TOMI Environmental Solutions (TOMZ): Customer Map and Commercial Signals for Investors

TOMI Environmental Solutions sells and licenses SteraMist® disinfection equipment and validation/servicing to healthcare, life sciences, education, food safety, and franchise decontamination operators; revenue stems from equipment sales, recurring service/validation contracts, and strategic integration partnerships with enclosure manufacturers. Investors should view TOMI as a niche equipment-and-services provider with global registration reach, short-term sales dynamics, and concentrated product risk around the SteraMist brand. Learn more about how this analysis is produced at https://nullexposure.com/.

How TOMI monetizes and the operating posture investors need to know

TOMI derives most of its revenue from sales and service of a single family of products—SteraMist BIT and SteraMist Environment Systems—and organizes go-to-market through direct sales, validation services, and channel/partner integrations. The company discloses no long-term customer contracts, operates with global registrations in 50 U.S. states, D.C., Canada and ~40 other countries, and functions as a manufacturer, licensor, seller and service provider for its core product, which concentrates commercial risk on continued SteraMist adoption. These characteristics produce revenue volatility, dependence on partner distribution, and upside tied to integration wins with enclosure and cleanroom providers. For deeper corporate relationship intelligence visit https://nullexposure.com/.

Customer relationships and documented engagements (source-by-source)

Below are the relationships identified in TOMI’s public filings and press releases; each entry includes a concise description and the cited source.

BeSpoke Pharmaceuticals

TOMI sold an additional SteraMist Hybrid System to BeSpoke Pharmaceuticals after an earlier channel sale to Indigo Pharmaceutical, indicating penetration into contract pharmaceutical manufacturing for 503B products. This relationship is disclosed in TOMI’s FY2024 10‑K filings.

Bonneville Joint School District No. 93

In November 2024 the Bonneville Joint School District No. 93 integrated SteraMist technology into its cleaning protocols, demonstrating K–12 adoption of TOMI’s surface-decontamination solutions. This is described in the company’s FY2024 10‑K.

Crank and Boom

TOMI entered the desserts and ice-cream vertical with a deployment at Crank and Boom during 2024, signaling expansion into specialty food operations for surface sanitation. The mention comes from TOMI’s FY2024 10‑K.

EMEA Group, Inc.

TOMI announced that EMAQ Group, Inc. purchased twenty SteraMist Environment Systems for $1,180,280 on July 24, 2024, representing a material OEM/channel sale in the EMEA region. This revenue event is recorded in TOMI’s FY2024 10‑K.

Indigo Pharmaceutical, Inc.

TOMI executed a first purchase agreement with Indigo Pharmaceutical—described as one of the largest private pharmaceutical companies—covering a SteraMist Environment System and validation services for a vivarium facility in Mexico. Details are in the FY2024 10‑K.

Lakeview Farms

TOMI expanded into the desserts and ice-cream industry with Lakeview Farms in 2024, indicating targeted wins in food safety segments outside core pharma and healthcare. The win is cited in TOMI’s FY2024 10‑K.

Mayorga Coffee

TOMI made an entry into the coffee industry with Mayorga Coffee during 2024, reflecting product diversification into food and beverage hygiene use cases. This is detailed in the FY2024 10‑K.

National Institute of Forensic Medicine (IPFN) in Malaysia

On October 24, 2024 TOMI secured a contract with Malaysia’s National Institute of Forensic Medicine, marking a government/institutional win in Southeast Asia. The contract is disclosed in the FY2024 10‑K.

Organea Terra SRL

Organea Terra SRL is listed as a 2024 coffee-industry customer, showing additional international traction in specialty food processing segments. This is in TOMI’s FY2024 10‑K.

Pfizer, Inc.

TOMI lists Pfizer among its clientele, indicating enterprise-level life sciences adoption and likely recurring service relationships at major pharmaceutical facilities. The reference to Pfizer is included in the FY2024 10‑K.

St. Jude Hospital

A long-standing relationship with St. Jude Hospital (customer since 2021) expanded in 2024 when the hospital purchased three additional SteraMist Surface Units, illustrating referral-driven upsell in healthcare. This expansion is described in TOMI’s FY2024 10‑K.

Trauma and Casualty Team (T.A.C.T.) franchises

TOMI sold SteraMist iHP equipment and BIT Solution totaling $175,000 to T.A.C.T. franchises—an 18-franchise national decontamination provider—demonstrating growth in franchise channel deployments. The sale was announced via Quiver Quant news in FY2025.

Hudson Global Ventures, LLC

TOMI granted an equity line of credit arrangement giving Hudson Global Ventures the right to purchase up to $20 million of common stock over 24 months, representing a financing relationship rather than a customer sale. This is detailed in a GlobeNewswire release reporting the FY2025 ELOC filing.

ESCO Micro Pte. Ltd.

ESCO Micro is named as a strategic enclosure-manufacturer partner in a $3 million custom integration pipeline, positioning TOMI to embed SteraMist into ESCO’s enclosures for life-sciences customers. The partnership is cited in a GlobeNewswire release in November 2025.

Nuaire, Inc.

Nuaire is identified among enclosure-manufacturer partners for a custom integration pipeline, supporting TOMI’s channel strategy to integrate SteraMist into modular cleanroom and cabinet systems. This is described in the GlobeNewswire November 2025 release.

Pharma Biotech System Components (PBSC)

PBSC is included in TOMI’s list of enclosure-manufacturer partners for integration work totaling $3 million, reinforcing the company’s focus on life-sciences equipment integrations. Source: GlobeNewswire, November 2025.

Steelco S.p.A.

Steelco S.p.A. is cited as a strategic partner in TOMI’s custom integration pipeline, highlighting collaboration with established European cleanroom and sterilization equipment vendors. The disclosure is in the GlobeNewswire November 2025 announcement.

Total Clean Air

TOMI designated Total Clean Air as its Preferred European Partner and announced integration of SteraMist iHP into TCA’s modular cleanroom platform, signaling a coordinated EU market push and product embedding. Multiple press releases (GlobeNewswire Nov 2025; GlobeNewswire Mar 3, 2026) document this FY2025–FY2026 relationship.

Thermo Fisher Scientific

TOMI lists Thermo Fisher Scientific among its clientele, indicating services or equipment sold into leading laboratory supply and facility networks. The reference appears in TOMI’s FY2024 10‑K.

Getinge AB

Getinge AB is listed as one of the enclosure-manufacturer partners in TOMI’s custom integration pipeline, pointing to enterprise-level OEM integrations for the life-sciences sector. This partnership is noted in the GlobeNewswire November 2025 release.

Ares Scientific

TOMI announced a win from East Coast distributor Ares Scientific that delivered a new university client and SIS platform deployment, demonstrating distributor-led growth in academic channels. This was reported in TOMI’s Q3 2025 results via GlobeNewswire.

Total Clean Air Limited (modular CES integration)

A GlobeNewswire release in January 2026 documents SteraMist iHP fully integrated into Total Clean Air Limited’s modular cleanroom architecture, marking the first deployment of iHP within that modular platform. The January 20, 2026 press release provides the detail.

What these relationships mean for investment risk and upside

  • Concentration on a single product family drives both upside (clear product positioning) and risk (single-point failure if SteraMist loses market preference); this is a company-level signal from TOMI’s FY2024 disclosures that SteraMist accounts for the majority of revenue.
  • Short-term contract profile: TOMI discloses that it does not maintain long-term customer contracts, producing revenue episodicity and reliance on continual new sales and partner integrations.
  • Global footprint with North American dominance: The company reports global registrations and material domestic revenue (U.S. revenue was $6,098,000 of $7,739,000 total in FY2024), supporting a strategy that blends domestic sales with selective international channel partnerships.
  • Hybrid go-to-market: TOMI functions as a manufacturer, licensor, seller and service provider and pursues both direct customers (Pfizer, Thermo Fisher, hospitals) and integration partners (Getinge, ESCO, Total Clean Air), which diversifies routes-to-revenue while increasing execution complexity.

For an investor-ready relationships dashboard and verification links, visit https://nullexposure.com/.

Actionable signals and next steps for investors

  • Monitor TOMI’s integration pipeline conversion with enclosure partners (Getinge, ESCO, Steelco, PBSC, Nuaire) as the primary near-term revenue engine.
  • Track recurring-service uptake at enterprise clients (Pfizer, Thermo Fisher, hospitals) for evidence of stickiness beyond the initial equipment sale.
  • Watch cash and dilution dynamics tied to the Hudson Global Ventures ELOC and any further financings, since TOMI’s sales cadence is short-term contract driven.

For a model-ready company relationship brief and continuous monitoring, go to https://nullexposure.com/.

Bold takeaway: TOMI is a focused equipment-and-service vendor with validated enterprise and institutional customers and a clear partner-driven strategy, but investors must price in short-term contract exposure and product concentration risk.